Melanoma Margins Trial (MelMarT): A Phase III Multi-Centre Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma.

Brief description of study

You can participate in this study if you are diagnosed with skin melanoma stage 2. This study will determine whether there is a difference in disease free survival for patients treated with either a 1cm excision margin or 2cm margin for clinical stage II, primary skin melanoma. The study is designed to be able to prove or disprove that there is no difference in risk of melanoma recurrence between the two groups of patients. This study is designed to show that the risk of long-term pain associated with surgery can be reduced. A 1cm excision margin will reduce the risk of long-term pain and will reduce surgical complication rates. A 1cm excision margin will have an impact on improved quality of life for patients and change the use of local healthcare resources. Once determined as being eligible, patients will be randomized 1:1 to either a 1 cm excision margin or a 2 cm excision margin, in combination with a staging sentinel lymph node (the first lymph node to which cancer cells are most likely to spread from a primary tumor).


Clinical Study Identifier: s22-00510
ClinicalTrials.gov Identifier: NCT03860883
Principal Investigator: Erica Brooke Friedman.
Other Investigators: Nila Theresa De La Rosa, Maya Dimitrova, Zachary Brown, Marianna Shvartsbeyn, Jeffrey S. Weber, George Jour, Richard L Shapiro, Russell S Berman, Kathleen M Madden, Janice Mehnert.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.